March 17, 2010

SymBio Pharmaceuticals Limited.
Fuminori Yoshida
Representative Director
President and Chief Executive Officer

NDA Submission for Bendamustine HCl (SyB L-0501) in Taiwan
TOKYO, Japan, March 17, 2010 -- SymBio Pharmaceuticals Limited (”SymBio”) today announced that
InnoPharmax Inc. submitted a New Drug Application (NDA) to the Taiwan Food and Drug
Administration (TFDA) for bendamustine HCl on February 6, 2010, to treat patients with indolent
non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL) and multiple myeloma (MM).
InnoPharmax executed a license agreement with SymBio (March, 2008) for the exclusive right todevelop and commercialize bendamustine in Taiwan.
Bendamustine was approved in Hong Kong by the Department of Health (DH) on December 30, 2009,and in Singapore by the Health Sciences Authority (HSA) on January 20, 2010, for use in patientswith indolent non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). In Japan,
SymBio submitted a New Drug Application (NDA) for bendamustine to the Pharmaceuticals andMedical Devices Agency (PMDA) under priority review on October 30, 2009, after receiving orphan
drug designation for refractory and relapsed indolent NHL, and mantle cell lymphoma.
SymBio is working closely with its valued partners in Asia Pacific to expand the availability of
bendamustine for the treatment of oncology patients throughout the region as expeditiously aspossible.

[SyB L-0501]
SymBio holds an exclusive right to SyB L-0501, the company’s first drug candidate, from Astellas
Deutschland GmbH (“Astellas”) for development and commercialization in Japan, China (HK),Taiwan, Korea and Singapore. SymBio and Eisai have executed license agreements forco-development and commercialization of SyB L-0501 in Japan (August, 2008), and exclusive
development and commercialization of bendamustine in Korea and Singapore (May, 2009). Cephalon,Inc., which holds the right to bendamustine in North America, has signed a license agreement withSymBio for the development and commercialization right to China (March, 2009). The drug iscurrently on the market for the treatment of patients with indolent NHL and CLL in the U.S., and islisted as first line therapy for indolent NHL and mantle cell lymphoma in the NCCN (NationalComprehensive Cancer Network) Clinical Practice Guidelines in Oncology, the recognized standard
for clinical policy in oncology. Mundipharma International Corp. Ltd. holds the right to bendamustinein Europe.

[InnoPharmax Inc.]
Established in 2005, InnoPharmax’s Research and Development group works on the development ofnovel delivery vehicles to improve drug in-vivo performance, and is fully dedicated to conducting
clinical research for new drugs in oncology and immunology with the aim of bringing clinical benefits
to patients suffering from unmet medical needs.

[Company Profile]
SymBio Pharmaceuticals Ltd. was established in March, 2005, by Fuminori Yoshida, who previously
served concurrently as Corporate VP of Amgen Ltd., and President of Amgen Japan (now Takeda Bio
Development Center Limited). The company’s underlying corporate mission is “delivering hope topatients in need,” as it aspires to be a leading specialty pharmaceutical company in Asia Pacificdedicated to addressing underserved medical needs in oncology, hematology, and autoimmune
disease.

[Contact]
SymBio Pharmaceuticals Limited.
Hiroki Maekawa,Corporate Officer,
Head of Corporate Division
Tel: +081(0)3 5472 1125
URL: http://www.symbiopharma.com/